Blue Owl

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Capital on Tap is a provider of a comprehensive small business credit card and spend management platform designed to assist small business owners in managing their expenses and accessing funding. The platform features a streamlined application process that takes just two minutes, allowing most applicants to receive instant credit decisions. With Capital on Tap, businesses can issue unlimited employee cards, benefit from high credit limits, and earn cashback rewards on all purchases. The company has dedicated the past decade to understanding the needs of small business owners and has garnered recognition as one of Europe’s fastest-growing businesses. To date, over 200,000 small business customers have utilized their services, collectively spending more than $5 billion on Capital on Tap Business Credit Cards. By simplifying business funding and spending, Capital on Tap aims to save time and money for its users.

Databricks Inc. offers a unified data analytics cloud platform that simplifies data engineering and supports collaborative data science. Its core product, Databricks, enables organizations to process and analyze large datasets efficiently, leveraging tools like Apache Spark. The platform is designed for real-time experimentation and robust deployment of production applications, catering to developers and data scientists. Additionally, Databricks provides Databricks Delta, a data management system that combines the scalability of a data warehouse with low-latency streaming capabilities. The company also offers MLflow for managing the machine learning lifecycle and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including healthcare, finance, manufacturing, and telecommunications. Founded in 2013 and headquartered in San Francisco, with additional offices in London, Amsterdam, and Bengaluru, Databricks has established strategic partnerships to enhance its offerings and foster innovation in data and AI technologies.

Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in developing treatments for patients with autoimmune diseases, organ transplantation needs, and neurodegenerative disorders. The company's lead product is tegoprubart, an anti-CD40L antibody designed to target the CD40L pathway, which has significant therapeutic potential. Additionally, Eledon focuses on disorders affecting the ear, nose, and throat, with its lead product OP0201 being a surfactant-based nasal aerosol aimed at patients at risk for otitis media. The company also explores foam-based drug delivery technologies, OP0101 and OP0102, for delivering medications to the ear, nose, and sinus cavities. Eledon Pharmaceuticals was previously known as Novus Therapeutics, Inc. before rebranding in January 2021.

CloudPay is a provider of managed global payroll services, offering a unified cloud-based platform designed for multinational organizations. Its solution delivers end-to-end payroll management, ensuring consistent and compliant payroll processing across over 130 countries in more than twenty-five languages. By standardizing payroll functions, CloudPay helps organizations enhance efficiency, streamline compliance, and gain better visibility into payroll performance and costs. The company leverages over twenty years of industry experience and has successfully served more than 2,500 multinational entities. CloudPay has been recognized for its innovative technology and service, receiving multiple awards, including accolades for Global Payroll Transformation and Payroll Software Product of the Year.

TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

TravelPerk is a comprehensive platform that streamlines business travel management by integrating booking, reporting, and support into a single tool. It enables users to easily book flights, hotels, and car rentals while ensuring adherence to company policies. The platform offers a wide range of travel options and features, including automated policies, expense integrations, and customer service support. With its user-friendly interface and advanced technology, TravelPerk helps organizations manage their travel needs efficiently, control costs, and simplify the overall booking process for employees. By combining various travel services into one solution, it aims to enhance the travel experience for businesses and reduce the complexities associated with managing business trips.

AlphaSense, Inc. is a market intelligence platform that specializes in information discovery for research professionals. Founded in 2007 and headquartered in New York, the company operates additional offices in London, Helsinki, Pune, and the U.S. Its platform allows users to efficiently search and analyze a wide range of financial data, including filings, research reports, and news, by utilizing natural language processing and advanced search algorithms. With nearly 2,000 enterprise clients, including a significant number of S&P 500 companies, AlphaSense empowers organizations to make informed business decisions quickly and confidently. The platform's capabilities include setting alerts and navigating through vast amounts of data to extract crucial insights across various industries.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer treatment through innovative diagnostics. The company's CELsignia diagnostic platform utilizes living tumor cells to uncover specific cellular processes that drive cancer in individual patients. This approach enables the identification of new cancer sub-types that traditional molecular diagnostics may overlook, ultimately expanding therapeutic options. Celcuity is developing the CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer and the CELsignia MP test for diagnosing 11 sub-types across various cancers, including breast, lung, colon, ovarian, kidney, and bladder. The company is also advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTOR inhibitor, currently being evaluated in a Phase 3 clinical trial for patients with advanced HR+/HER2- breast cancer.

Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company’s primary aim is to address female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Context's lead program is Apristor (Onapristone XR), an investigational drug currently in Phase 2 trials for treating progesterone receptor positive metastatic breast and ovarian cancers. The company is also advancing CTX-030916, a potential oral antiprogestin designed for uterine fibroids and endometriosis. Additionally, Context is engaged in a discovery-stage program targeting Sigma1 and has developed CTIM-76, a bispecific antibody aimed at redirecting T-cell-mediated lysis towards malignant cells expressing CLDN6. Through its focused pipeline, Context Therapeutics is committed to creating effective treatments for patients with solid tumors.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Prima Capital Advisors LLC, located in Scarsdale, New York, offers investment advisory and asset management services focused on commercial real estate debt. The firm caters to a diverse clientele, including insurance companies, endowments, corporate and public pension plans, and sovereign wealth funds. Prima Capital specializes in a range of investments, such as commercial mortgage whole loans, commercial mortgage-backed securities, select commercial mortgage "B" notes, mezzanine loans, and preferred shares issued by real estate investment trusts. Through open-ended funds and separate accounts, the firm aims to provide clients with consistent income-generating strategies.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

RLDatix is a software company focused exclusively on patient safety and quality improvement.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Vestwell is a developer of a digital savings platform focused on creating retirement plans for employees. The platform provides automated retirement investing options tailored for registered investment advisers (RIAs), aligning with regulatory requirements and various defined contributions for companies and their employees. By facilitating compliance and automation, Vestwell enables advisers to better engage with their clients in managing retirement savings.

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Wellfleet Credit Partners credit business Invetsment Firm .

6Sense is a company that transforms how organizations manage and convert sales pipelines into revenue. It offers a predictive intelligence platform that leverages artificial intelligence, big data, and machine learning to capture anonymous buying signals and provide insights into customer behavior. By identifying the right accounts and suggesting optimal communication channels and messages, 6Sense helps sales, marketing, and customer success teams enhance pipeline quality and accelerate sales processes. This technology not only reduces guesswork and friction in the sales journey but also aims to increase conversion rates and facilitate predictable revenue growth. Through its omnichannel connectivity and visibility, 6Sense enables revenue teams to make informed decisions based on buyer intent data and other predictive analytics.

Ascentium Group provides financial services.